Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Public ClinicalTrials.gov record NCT05696717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Study identification
- NCT ID
- NCT05696717
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 102 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2023 (Actual)
- Primary completion
- Jan 2026 (Estimated)
- Completion
- Jan 2028 (Estimated)
- Last update posted
- Sep 5, 2025
2023 – 2028
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Movement Disorders Center of Arizona | Scottsdale | Arizona | 85258 | — |
| The Parkinson's and Movement Disorder Institute | Fountain Valley | California | 92708 | — |
| UC San Diego Movement Disorder Center | La Jolla | California | 92037 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | — |
| Stanford Neuroscience Health Center | Palo Alto | California | 94304 | — |
| Medstar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Parkinson's Disease And Movement Disorders Center of Boca Raton | Boca Raton | Florida | 33486 | — |
| SFM Clinical Research, LLC | Boca Raton | Florida | 33487 | — |
| Aqualane Clinical Research | Naples | Florida | 34105 | — |
| Neurostudies, Inc | Port Charlotte | Florida | 33952 | — |
| University of South Florida Ataxia Research Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30329 | — |
| Hawaii Pacific Neuroscience | Honolulu | Hawaii | 96817 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Northshore University Health System | Glenview | Illinois | 60026-1339 | — |
| University of Kansas Medical Center Research Institute, Inc. | Kansas City | Kansas | 66160 | — |
| Brigham and Women's Hospital (Neuromuscular Division) | Boston | Massachusetts | 02115 | — |
| Massachusetts Chan Medical School | Worcester | Massachusetts | 01655 | — |
| Quest Research Institute | Farmington Hills | Michigan | 48334 | — |
| NYU Langone Health NYU Dysautonomia Center | New York | New York | 10016 | — |
| The Neurological Institute at Columbia University Medical Center | New York | New York | 10032 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Movement Disorders and Autonomic Disorders Clinic; University of Utah | Salt Lake City | Utah | 84108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05696717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 5, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05696717 live on ClinicalTrials.gov.